Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin's Lymphoma
– GRC 54276 is one of the many novel molecules from Glenmark’s resident, Innovative Medicines Group, specializing in the development
Read More